Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.

Autor:	Miranda RN; Roberto N. Miranda, Rashmi Kanagal-Shamanna, Luis E. Fayad, Summer E. Hanson, John T. Manning Jr, Zijun Y. Xu-Monette, Patricia Fox, Roland L. Bassett, Ken H. Young, L. Jeffrey Medeiros, The University of Texas MD Anderson Cancer Center; Alonso R. Miranda, University of Houston, Houston; Eid Mustafa, Plastic and Reconstructive Surgery, Wichita Falls; Steven Sanchez, Pathology Associates of Tyler, Tyler, TX; Mitual B. Amin, Oakland University William Beaumont School of Medicine, Royal Oak, MI; Nisreen Haideri, Saint Lukes Cancer Institute, Kansas City, MO; Govind Bhagat, Columbia University Medical Center, New York Presbyterian Hospital and Herbert Irving Comprehensive Cancer Center, New York, NY; Glen S. Brooks, Tufts University, Longmeadow; Ephram P. Hochberg, Massachusetts General Hospital; Matthew J. Carty, Brigham & Women's Hospital, Boston, MA; David A. Shifrin, Advocate Medical Group Plastic Surgery, Oak Lawn, IL; Dennis P. O'Malley, Clarient Laboratories/GE Healthcare, Aliso Viejo, CA; Shiyong Li, Emory University Hospital, Atlanta, GA; John A. Keech Jr, MultiCare Regional Cancer Center, MultiCare Health Systems, Tacoma, WA; Jorge J. Castillo, The Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI; Dongjiu Ye, Bioreference Laboratories, Elmwood Park, NJ; Douglas Clark, New Mexico Cancer Center, Albuquerque, NM; Tariq N. Aladily, The University of Jordan, Amman, Jordan; H. Miles Prince, Chan Y. Cheah, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Daphne de Jong, Vrije Universiteit Medical Center; Jan Paul de Boer, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Carlos E. Bacchi, Gabriela Gualco, Consultoria em Patologia, Botucatu, São Paulo, Brazil; Brady E. Beltran, Edgardo Rebagliati Martins Hospital, Lima, Peru; Zaher Chakhachiro, American University of Beirut Medical Center, Beirut, Lebanon., Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, Shifrin DA, O'Malley DP, Cheah CY, Bacchi CE, Gualco G, Li S, Keech JA Jr, Hochberg EP, Carty MJ, Hanson SE, Mustafa E, Sanchez S, Manning JT Jr, Xu-Monette ZY, Miranda AR, Fox P, Bassett RL, Castillo JJ, Beltran BE, de Boer JP, Chakhachiro Z, Ye D, Clark D, Young KH, Medeiros LJ
Jazyk:	angličtina
Zdroj:	Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Jan 10; Vol. 32 (2), pp. 114-20. Date of Electronic Publication: 2013 Dec 09.
DOI:	10.1200/JCO.2013.52.7911
Abstrakt:	Purpose: Breast implant-associated anaplastic large-cell lymphoma (ALCL) is a recently described clinicopathologic entity that usually presents as an effusion-associated fibrous capsule surrounding an implant. Less frequently, it presents as a mass. The natural history of this disease and long-term outcomes are unknown. Patients and Methods: We reviewed the literature for all published cases of breast implant-associated ALCL from 1997 to December 2012 and contacted corresponding authors to update clinical follow-up. Results: The median overall survival (OS) for 60 patients was 12 years (median follow-up, 2 years; range, 0-14 years). Capsulectomy and implant removal was performed on 56 of 60 patients (93%). Therapeutic data were available for 55 patients: 39 patients (78%) received systemic chemotherapy, and of the 16 patients (28%) who did not receive chemotherapy, 12 patients opted for watchful waiting and four patients received radiation therapy alone. Thirty-nine (93%) of 42 patients with disease confined by the fibrous capsule achieved complete remission, compared with complete remission in 13 (72%) of 18 patients with a tumor mass. Patients with a breast mass had worse OS and progression-free survival (PFS; P = .052 and P = .03, respectively). The OS or PFS were similar between patients who received and did not receive chemotherapy (P = .44 and P = .28, respectively). Conclusion: Most patients with breast implant-associated ALCL who had disease confined within the fibrous capsule achieved complete remission. Proper management for these patients may be limited to capsulectomy and implant removal. Patients who present with a mass have a more aggressive clinical course that may be fatal, justifying cytotoxic chemotherapy in addition to removal of implants.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu